PegBio (HKG:2565) said its next-generation GLP-1 receptor agonist CR059 has completed single-dose administration in a first-in-human clinical trial and generated one-month clinical observations, according to a March 6 Hong Kong bourse filing.
Shares of the biopharmaceutical company were down nearly 2% in Monday morning trade.
The study is evaluating the safety, tolerability, and pharmacokinetic and pharmacodynamic characteristics of CR059 in patients with type 2 diabetes mellitus, the company said.
Preliminary observations four weeks after a single dose showed improvements in glycated hemoglobin, fasting blood glucose, and overall glucose control, PegBio said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.